What Happened to Lineage-and Leukemia-Specific Antigens? Implications for Therapeutic Use of Monoclonal Antibodies
The development of hybridoma and monoclonal antibody technology by Köhler and Milstein in 1975  was certainly a major scientific event, without which the current workshop would not be held. Great expectations were clearly aroused in the immunologic and hematologic communities as a result of this technology. Specifically, the high expectations were related to the use of these antibodies in several areas, three of which we will discuss. In this report we hope to briefly review progress in the areas of (a) lineage-specific differentiation antigens, (b) leukemia-specific antigens, and (c) therapeutic use of monoclonal antibodies. Since the organizers of this meeting have requested that this be in the form of an editorial, we will attempt to conform.
KeywordsCell Surface Molecule Autologous Bone Marrow Transplantation Leukemia Associate Antigen Common Acute Lymphoblastic Leukemia Antigen Current Workshop
Unable to display preview. Download preview PDF.
- 2.Carroll L (1960) The annotated Alice. Bramhall, New York p 264Google Scholar
- 4.Platt JL, LeBien TW, Michael AF (1983) Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens. J Exp Med (in press)Google Scholar
- 8.Melink GB, LeBien TW (to be published) Construction of an antigenic map for human B cell precursors. J Clin ImmunolGoogle Scholar
- 9.Neudorf SML, Boue DR, LeBien TW, Kersey JH (to be published) The common acute lymphoblastic leukemia antigen may define recent migrants to the human thymus. Exp. HematolGoogle Scholar
- 19.Le Bien TW, Ash RC, Zanjani ED, Kersey JH (to be published) In vitro cytodestruction of leukemia cells in human bone marrow using a cocktail of monoclonal antibodies. In: Neth VR (ed) Modern trends in human leukemia.Google Scholar
- 20.Kaizer H, Levy R, Santos GW (1982) Autologous bone marrow transplantation in T-cell malignancies: Use of in vitro monoclonal antibody treatment of remission marrow to eliminate tumor cells. J Cell Biochem [Supp] 6: 41Google Scholar
- 21.Ritz J, Sallan S, Bast RC, Liptin JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schloss-man SF (1982) Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2: 60–63PubMedCrossRefGoogle Scholar
- 24.Tatsumi E, Sugimoto T, Minato K, Sagawa K, Civen C, Early A, Preisler H, Henderson E, Minowada J (1982) Heterogeneity of AML and CML blasts as determined by multiple monoclonal antibodies. Proc Am Soc Cl in OncolGoogle Scholar